What Ectica Technologies does

Ectica Technologies AG is a Swiss life-science tools company founded in 2015 as a spin-off of ETH Zurich and the University (Hospital) Zurich, headquartered in Bioggio (Canton Ticino) with R&D operations in Zurich. The company develops and commercializes the patented 3DProSeed® platform — a synthetic poly(ethylene glycol)-based hydrogel system engineered with in-depth density gradients at the hydrogel surface that enable cells to penetrate the 3D matrix without encapsulation. The platform is delivered in 96-well imaging-plate format (180-micron glass bottom, ANSI footprint), pre-assembled and hydrated, and is positioned as workflow-compatible with standard high-content screening infrastructure.

The company's commercial portfolio comprises two product families: the 3DProSeed Hydrogel Well Plate (core consumable SKU) and the 3DProSeed StromaLine collection — a catalog of pre-developed, assay-ready ex vivo tumor stromal models spanning cancer-associated fibroblasts from pancreatic, lung, and melanoma tissues, bone-marrow mesenchymal stromal cells, bone-marrow vascular niche co-cultures, and fibrosis-relevant fibroblastic models. Revenue is generated through (i) one-time catalog product sales to pre-clinical CROs and biopharmaceutical companies worldwide, and (ii) contract development and manufacturing services for CDMOs and OEM customers seeking custom hydrogel formulations, bioconjugation reactions, surface coatings, and soft polymeric particles. Go-to-market is sales-led and event-driven, with heavy reliance on conference participation (AACR, EACR, SLAS, Swiss Biotech Days, ELRIG) and free introductory videocalls as the primary technical-consultation funnel.

As a founder-controlled private company with 1–10 employees, Ectica has secured only modest disclosed non-dilutive capital (Horizon 2020 SME Instrument Phase 1 EUR 50,000 plus a Venture Kick award of approximately USD 11,000), relying primarily on grant funding, EU innovation programs, and product revenue rather than institutional venture capital. Named enterprise customers include Merck KGaA, and the company holds granted European patent protection (EPO 3049122) on its core density-gradient technology.

Name

Ectica Technologies

Legal name

Ectica Technologies AG

Website

https://ectica-technologies.com

Company type

Private

Founded year

2015

Operating status

Operating

Headcount range

1–10 employees

Short description

Ectica Technologies AG is a Swiss life-science tools company (spin-off of ETH Zurich and University Hospital Zurich) that develops and sells the patented 3DProSeed® synthetic hydrogel platform — including hydrogel well plates and pre-developed StromaLine tumor stromal models — to pre-clinical CROs and biopharmaceutical companies for 3D cell-based drug discovery.

Ownership category

akta.pro rank

Product category

3D Cell Culture Products

NAICS

Resin and Synthetic Rubber Manufacturing (32521)

SIC

Plastic Materials, Synth Resins & Nonvulcan Elastomers (2821)

akta.pro primary industry

Specialty Polymers & Resins (Engineered Materials) (IMAEABAK)

Keywords

• 3D cell culture
• Hydrogel research tools
• Tumor stroma models
• Drug discovery assays
• Cancer research products

Headquarters

HQ city

Zürich

HQ country

Switzerland

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain

Revenue model

1. 3DProSeed Hydrogel Products: Sale of pre-assembled 3DProSeed hydrogel plates and StromaLine pre-developed stromal models. Products include catalog items such as ECT.PS1.001.096 (single pack) and ECT.PS1.010.096 (Pack of 10) for hydrogel plates, and various StromaLine products for specific cancer types. Revenue is generated through direct product sales to research institutions, CROs, and biopharma companies.
2. Contract Development and Manufacturing Services: Custom hydrogel formulation development and manufacturing services for CDMOs and companies seeking tailored hydrogel solutions. Services include bioconjugation reactions of biocompatible polymers, hydrogel surface coatings, surface patterning, and soft polymeric particle development. Customization available in terms of chemistry, product format, and branding.

Pricing tiers

Go-to-market motion2 records

Distribution channels2 records

Marketing channels5 records

Core offering

Ectica Technologies develops and manufactures synthetic poly(ethylene glycol)-based hydrogel products (the 3DProSeed platform) and pre-developed ex vivo tumor stromal models (3DProSeed StromaLine) for 3D cell culture in drug discovery and cancer research. The products are sold as 96-well imaging plates delivered hydrated and ready for cell seeding, targeted at pre-clinical Contract Research Organizations and biopharmaceutical companies. The company also provides contract development and manufacturing of customized OEM hydrogel formulations, coatings and bioconjugation services.

Product overview

Ectica Technologies offers a portfolio centered on the 3DProSeed technology platform, which combines patented synthetic poly(ethylene glycol)-based hydrogels with 96-well imaging plate formats for 3D cell-based assays. The core 3DProSeed Hydrogel Well Plate provides the foundational technology featuring an in-depth density gradient that enables cell penetration without encapsulation. The 3DProSeed StromaLine collection extends the platform with pre-developed, assay-ready stromal models including cancer-associated fibroblasts (CAFs) from pancreatic, lung, and melanoma tissues, bone marrow mesenchymal stromal cells, bone marrow vascular niche co-cultures, and human fibroblastic cultures for fibrosis research. All StromaLine products come with optimized medium, reagents, and the compatible hydrogel plate as a complete system. The company also provides contract development and manufacturing services for customized hydrogel formulations.

Differentiator

Problem solved

Functional benefit

Brands

• 3DProSeed: Patented synthetic PEG-based hydrogel platform with in-depth density gradients for 3D cell culture in 96-well plates, delivered hydrated and ready for cell seeding
• 3DProSeed StromaLine

Products and services

• 3DProSeed Hydrogel Well Plate 96-well black glass-bottom imaging plate containing pre-assembled synthetic poly(ethylene glycol)-based hydrogels delivered hydrated and ready for cell seeding, with patented in-depth density gradients enabling cells to penetrate into the 3D matrix without encapsulation; standard ANSI footprint for high-content screening and microscopy workflows, used by CROs and biopharma researchers running 3D cell-based assays.
• 3DProSeed StromaLine Collection Family of pre-developed ex vivo tumor stromal models in 3DProSeed synthetic hydrogels, supplied as assay-ready 96-well plates with optimized medium and reagents for tumor-stroma interaction studies and drug screening.
• 3DProSeed StromaLine Pancreatic CAFs Pre-developed human stromal model with patient-derived pancreatic cancer-associated fibroblasts in synthetic 3D hydrogels, sold as a 96-well imaging plate for tumor-stroma interaction and anti-cancer drug screening studies.
• 3DProSeed StromaLine Lung CAFs Pre-developed human stromal model with patient-derived lung cancer-associated fibroblasts (CAFs) from invasive squamous cell carcinomas, supplied in synthetic 3D hydrogels in 96-well imaging plate format (catalog ECT.STRL.LUNCAF.096) for tumor-stroma interaction studies.
• 3DProSeed StromaLine Melanoma CAFs Pre-developed human stromal model with patient-derived malignant melanoma cancer-associated fibroblasts in synthetic 3D hydrogels, supplied in 96-well imaging plate format (catalog ECT.STRL.MECAF.096) for studying the stromal component of the melanoma tumor microenvironment.
• 3DProSeed StromaLine Bone-Marrow MSC 3D culture platform for multipotent stromal cells from normal adult human bone marrow on synthetic PEG-based hydrogel that supports deposition and assembly of native extracellular matrix resembling bone marrow stroma, supplied in 96-well format (catalog ECT.STRL.BMMSC.096).
• 3DProSeed StromaLine Bone-Marrow Vascular Niche Pre-developed co-culture system of human bone marrow mesenchymal stromal cells and endothelial cells in synthetic 3D hydrogels modelling the (peri)vascular niche for angiogenesis and vasculogenesis studies, supplied in 96-well format (catalog ECT.STRL.BMVAS.096).
• 3DProSeed StromaLine Human Fibroblastic Cultures 3D organotypic models using primary cardiac and pulmonary fibroblasts and primary human hepatic stellate cells in proprietary precast synthetic hydrogels, used to screen pro- and anti-fibrotic molecules via microscopy and biochemical biomarker analysis.
• Hydrogel Development and Manufacturing Services Contract development and OEM manufacturing services for customized hydrogel formulations, including bioconjugation of activated poly(ethylene glycols), hydrogel surface coatings and surface patterning, and soft polymeric particle development, with customization in chemistry, product format and branding for CDMOs and OEM partners.

Quantifiable outcome

• High-content screening-compatible stromal models enable new discoveries in oncology and fibrosis with minimal adaptation efforts
• +1 more outcomes

Named customers1 record

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Six partnerships are on record, tiered core and minor.

• Nordic BiosciencecoreStrategic or Co-development Partner · 13 December 2023Strategic alliance announced December 2023 to strengthen Nordic Bioscience's translational in vitro model offering. Nordic Bioscience offers specialized 3DPROFIB assays for fibrosis using their large biomarker library measuring extracellular matrix formation and degradation, combined with Ectica's hydrogel cell-based platform.
• Mestastop SolutionscoreStrategic or Co-development Partner · 18 October 2022Research collaboration to pursue novel platform creation on cancer metastasis. Mestastop has proprietary technologies around metastasis drug discovery and early predictive diagnostics. Ectica contributes hydrogel-based co-culture platforms for tumor-stroma interaction studies. Collaboration aims to share know-how in genetic engineering and functional phenotypic cell-based assays for metastasis research.
• SCREEN Holdings Co. LtdcoreTechnology or IntegrationJoint exhibition partnership at multiple conferences including AACR 2022 and PREDiCT 3D Tissue Models Summit. Collaboration on label-free 3D tomographic imaging of organotypic cultures developed in 3DProSeed hydrogel plate. SCREEN provides infrared laser-based optical coherence tomography technology for non-invasive imaging of tumoroids and organoids.
• University of Zurich, University Hospital Zurich, and EMPAminorStrategic or Co-development PartnerCTI/KTI project collaboration with Dr. Tackenberg at University of Zurich, Dr. Ehrbar at University Hospital Zurich, and Dr. Schmutz at EMPA. Project focuses on further developing applications and manufacturing aspects of 3DProSeed technology.
• Merck AcceleratorminorGTM or Marketing PartnerSelected participant in Merck Accelerator program, providing opportunity to internationalize business and reach global market. Part of Merck's innovation ecosystem supporting startups.
• InnoSuisse and Swiss Global EnterpriseminorGTM or Marketing PartnerSponsors and supporters of Ectica Technologies, enabling participation in international business development activities such as BioEurope conferences.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• InSphero: InSphero provides 3D organoid and spheroid disease models for drug discovery and toxicology. Like Ectica, it sells defined, assay-ready 3D cell-culture tools to pharma/CROs for oncology and metabolic disease research.
• MIMETAS: MIMETAS develops organ-on-chip and 3D tissue models for disease modeling and drug screening, including tumor-stroma interaction platforms. Directly comparable as a specialty 3D tissue-model tools vendor targeting the same biopharma buyer.
• Cellink (BICO): Cellink/BICO develops bioinks, hydrogels, and bioprinting platforms for 3D cell culture, with comparable PEG/hydrogel chemistries positioned for cancer research and tissue engineering. Overlaps in hydrogel chemistry, lab automation, and life-science-tools GTM.
• QNano / QGel Bio: QGel develops synthetic, animal-free PEG-based hydrogels for organoid and 3D cell culture in drug discovery. Most direct technical competitor given shared PEG hydrogel chemistry and oncology drug-discovery customer base.

Emerging players

• Lena Biosciences: Lena Biosciences offers 3D cell culture and tissue-engineering hydrogel platforms for cancer and drug-discovery research. Comparable as a smaller specialty hydrogel-tools peer with similar oncology/cancer-research focus.
• Organovo: Organovo develops 3D bioprinted human tissue models for drug discovery and disease research, with a focus on oncology and fibrosis. Comparable as a tissue-modeling platform targeting pharma screening applications.
• Emulate: Emulate develops organ-on-chip platforms (Liver-Chip, etc.) for preclinical drug testing. Adjacent to Ectica as an emerging alternative 3D in-vitro model platform for pharma R&D.

Broad incumbents

• Corning Life Sciences: Corning Matrigel and Corning spheroid plates dominate the 3D cell-culture and organoid tools market and compete with Ectica's hydrogels in the same pharma/CRO applications. Broad incumbent in cell-culture plastics and matrices.
• Thermo Fisher Scientific: Thermo Fisher sells Gibco/Geltrex 3D matrices and a broad cell-culture portfolio directly competing with Ectica in tumor-stroma and high-content screening applications. The largest incumbent in life-science research tools.
• Lonza Bioscience: Lonza provides primary cells, 3D cell-culture reagents, and custom hydrogel/media services for pharma R&D. Competes in the same cell-culture tools space with a much broader portfolio and global manufacturing footprint.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/ectica-technologies
• Xx.com/ecticatech

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ectica Technologies